January 25, 2022
Life Sciences
  • The FDA restricted the use of COVID-19 antibody treatments that don’t appear effective against the Omicron variant. The agency saying the decision will be in place while the strain is dominant. Some health systems stopped using the treatments weeks ago, although providers have said that other treatments to combat the variant are in short supply. (Article here)